New Centre Brings Genomics, Cellular Therapies and Bone Marrow Transplants Under One Roof to Transform Blood Cancer Treatment

In a significant step forward for blood cancer care in India, Fortis Memorial Research Institute (FMRI), Gurugram, has launched the country’s first Centre of Excellence for Myeloma and Lymphoma, a specialised facility aimed at delivering precision-driven and personalised treatment for patients battling complex blood cancers.

The newly launched centre is designed to bring together advanced diagnostics, genomics, stem cell transplantation, cellular therapies, clinical research and comprehensive patient support services on a single integrated platform. Built around the philosophy of “One Disease. One Doctor. One Focus.”, the initiative seeks to simplify and strengthen care for patients suffering from myeloma and lymphoma, two of the most challenging forms of blood cancer.

Hospital officials said the centre has been created to address the growing complexity of blood cancer management through customised treatment pathways and close collaboration among experts from multiple specialties. By combining cutting-edge science with patient-centric care, the institute hopes to improve outcomes, accelerate access to innovation and set new benchmarks in hematologic oncology.

Speaking at the launch, Dr Rahul Bhargava, Principal Director and Chief, Hematology, Hemato-Oncology and Bone Marrow Transplant at FMRI, described the centre as a major milestone in India’s cancer care landscape.

"The launch of India’s first Centre of Excellence for Myeloma and Lymphoma marks a significant step forward in our commitment to delivering highly specialised care for patients battling complex blood cancers. Just as bispecific antibodies bring immune cells and cancer cells together to achieve better outcomes, this centre brings together the brightest minds across genomics, genetics, pathology, translational science, data analytics, hematology, radiation oncology, cellular therapy, CAR-T and clinical research," he said.

Dr Bhargava added that the centre aims to create an ecosystem where scientific discoveries can be rapidly translated into personalised treatment strategies, enabling patients to access advanced diagnostics, innovative therapies and clinical trials. "Our vision is simple yet transformative: to bring the right expertise together, at the right time, for every patient, and ultimately redefine the future of blood cancer care in India," he said.

Highlighting the growing role of precision medicine, Dr Shrinidhi Nathan, Consultant, Molecular Hematology and Oncology at FMRI, said advances in genomics are changing the way blood cancers are diagnosed and treated.

"Genomics is redefining blood cancer care by enabling us to understand each patient's disease at a molecular level. Through advanced genomic profiling, we can identify actionable mutations, personalise treatment strategies, monitor disease more precisely and connect patients to targeted therapies and clinical trials," Dr Nathan said.

According to him, integrating expertise from genomics, pathology, translational science and clinical oncology will help accelerate the journey from scientific discovery to better patient outcomes while shaping the future of precision medicine in hematologic cancers.

Mr Yash Rawat, Senior Vice President and SBU Head at FMRI Gurugram, said the launch strengthens the hospital’s position as a leader in advanced cancer and transplant care.

"The Centre of Excellence for Myeloma and Lymphoma represents a significant milestone in India’s hematology landscape. The initiative is expected to serve as a national referral hub for patients seeking specialised treatment while also contributing to clinical research, innovation and the development of future standards of care in hematologic oncology," he said.

With blood cancers becoming increasingly complex and requiring highly specialised interventions, the new centre is expected to provide patients access to a comprehensive spectrum of care—from early diagnosis and precision treatment planning to advanced therapies and long-term disease management—all under one roof.

The launch signals a new chapter in India’s fight against blood cancers, placing precision medicine, multidisciplinary expertise and research-led care at the heart of treatment for myeloma and lymphoma patients.